Navigation Links
Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists
Date:5/29/2009

TUSTIN, Calif., May 29 /PRNewswire/ -- Exiqon Diagnostics, announced today a strategic commercial partnership with MedTrust Online, an innovative, comprehensive internet based solution provider for oncologists that offers clinically useful knowledge on the latest topics in cancer treatment. Exiqon Diagnostics, a leader in individualizing cancer care through novel molecular and cell-based (the Oncotech EDR(R) Assay) clinical laboratory services, will become a content partner by providing a comprehensive suite of oncology molecular diagnostics services to MedTrust Online's Oncocentric oncology portal.

MedTrust Online will add Exiqon Diagnostics service offerings, extensive clinical studies, insurance/billing information, order forms, and live forum case studies available to MedTrust's growing oncology health care provider user base consisting of thousands of medical, gynecologic and surgical oncologists as well as pathologists and support staff nationwide.

"We are pleased to add Exiqon Diagnostics to the growing list of molecular diagnostic companies providing content on the MedTrust Online oncology portal," said Matt Sargent, Vice President of Molecular Diagnostics for MedTrust Online. "Molecular diagnostic testing options and drug reimbursement data are the two most heavily requested topics from our oncology user base. Our Oncocentric portal allows oncologists to rapidly find the information that they need on new molecular diagnostics to better practice personalized medicine."

"Partnering with MedTrust offers a unique opportunity to present molecular and cell-based testing options and information to medical oncologists in an unbiased and confidential forum," stated Erik Holmlin, Chief Commercial Officer of Exiqon. "We believe MedTrust can provide patient care teams with important testing information that will help them make better informed and individualized treatment decisions for their patients."

'/>"/>
SOURCE MedTrust Online
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Norgen Biotek Corp. Announces OEM Manufacturing & Supply Agreement with Exiqon A/S
2. Exiqon Announces Positive Clinical Data From EORTC Clinical Trial Showing Oncotech EDR Assay Predicts Resistance to Platinum-Based Therapy in Ovarian Cancer
3. Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc.
4. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
5. Report Regarding the Managements and Closely Related Parties Transactions With Securities in Exiqon A/S
6. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
7. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
8. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
9. Exiqon: Major Shareholder Announcement
10. Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting
11. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 Pressure BioSciences, Inc. (OTCQB: PBIO) ... will host a teleconference to discuss its First Quarter ... The teleconference information is provided below: Date: ... Time (EDT) Dial-in: (800) 875-3456 (U.S.); (800) ... Passcode: VS22823 For those unable to participate ...
(Date:5/23/2013)... 2013 During the conduct of ... adhere to principles of good clinical practice (GCP) ... Dr. Jeremy Lim, Fellow, Clinical Development at Novartis ... ,     Understand the International Conference on Harmonization (ICH) ... regulations for the conduction of clinical trials , ...
(Date:5/23/2013)... SynCardia Systems, Inc. ( http://www.syncardia.com ), manufacturer of ... CE (Europe) approved Total Artificial Heart, announced today that ... than 380,000 visitors annually, is featuring the SynCardia ... portable driver as part of its $3 million Bodyworks ... kind. , “BodyWorks combines the latest technology with ...
(Date:5/23/2013)... 2013 Bed bugs already cost Alton Housing ... still ongoing, a report from kmov.com suggested that the said ... bug treatment. Meanwhile, to be of help, My Cleaning Products ... bed bug exterminator service. , The report, which ... so far spent $35,000 for bed bug elimination, ...
Breaking Biology Technology:Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3Bed Bug Exterminator Service Could Cost AHA $250K, My Cleaning Products Gives Tips How to Save Apartments from Costly Bed Bug Treatment 2
... Jan. 26 WellCentive, LLC,today announced that WellCentive ... Information Exchange) as its patient registry and disease,management ... use of WellCentive Registry, more than 1,000 my1HIE ... will be better able to,provide preventive care services ...
... Jan. 26 Sirion Therapeutics, Inc., a privately held ... Application (NDA) for ganciclovir ophthalmic gel, 0.15%, has been ... Administration (FDA). Sirion Therapeutics is seeking approval for ganciclovir ... caused by the herpes simplex virus. The FDA has ...
... YORK, Jan. 26 Netsmart Technologies, Inc., a ... health and human services organizations, today announced it ... the New York State Association of Alcoholism and ... company,s comprehensive education, online learning and learning management ...
Cached Biology Technology:my1HIE(sm) Implements WellCentive Registry 2my1HIE(sm) Implements WellCentive Registry 3Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 2Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes 3Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 2Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 3
(Date:5/23/2013)... the new mechanism by which estrogen suppresses lipid synthesis ... potential new approach toward treating certain liver diseases. ... believe they are changing long-held views in the field. ... the journal Science Signaling . , "The dogma ... been that only receptors located in the nucleus respond ...
(Date:5/23/2013)... have succeeded in treating cerebral palsy with autologous cord ... a 2.5 year old boy had been in a ... Just two months after treatment with the cord blood ... following months, the child learned to speak simple sentences ... a Korean study, dispel the long-held doubts about the ...
(Date:5/22/2013)... CITY, May 22, 2013 U.S. Forest Service scientists ... that, with funding from the TKF Foundation, will examine ... communities and individuals recover from tragedy. , The TKF ... of six projects selected for grant funding. In addition ... sacred spaces in recovery and resiliency, the 3-year, $585,000 ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... 19 2011) Bone marrow-derived stem cells (BMDCs) have been ... to different cell populations in a variety of organs under ... aimed at repairing damaged brain tissue or helping to restore ... to the cerebellum at the back of the brain. In ...
... and neglected disease drug discovery, MMV and SCYNEXIS, Inc. have ... compounds with antimalarial activity and will provide it to researchers ... Box have confirmed activity against the blood-stage of P. ... and were selected by experienced medicinal chemists from an ...
... (IRSF) announced today that it is awarding over $1.5M to ... diverse topics from basic science and disease pathology to developing ... the world,s largest private source of funding for biomedical and ... spending of over $26M since 1998. It is the ...
Cached Biology News:Bone marrow-derived cells differentiate in the brain through mechanisms of plasticity 2MMV and SCYNEXIS offer 400 active compounds for neglected disease drug research at no cost 2IRSF awards over $1.5 million for basic and translational research for Rett syndrome 2IRSF awards over $1.5 million for basic and translational research for Rett syndrome 3
... Salmonella typhimurium The genus Salmonella is a ... composed of Gram-negative bacilli that are facultative and ... "H" or flagellar antigen (phase 1 & 2), ... LPS moiety) and the "Vi" or capsular antigen ...
... With 36 mg/L sodium pyruvate, 50 ... 1000 mg/L glucose, calcium chloride, and magnesium ... solution (BSS) in tissue culture is generally ... In 1885, Sydney Ringer developed a solution ...
... The micro 1 is a dramatic breakthrough ... from 1mL with 10nL resolution, the micro 1 ... benchtop dispenser. And, the micro 1 never needs ... , Touch Screen programming on an LCD Display ...
... Rabbit polyclonal to Rad51 ( ... Antigen: Synthetic ... to N terminal amino acids 15-29 ... Entrez Gene ID: 5888 ...
Biology Products: